Last updated: April 28, 2026
Adempas (riociguat): Clinical Trials Update, Market Analysis, and 2024–2029 Projection
Adempas (riociguat) is an oral soluble guanylate cyclase (sGC) stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in multiple patient subgroups. Commercial trajectory is shaped by (1) long-duration therapy in PAH and CTEPH, (2) competitive pressure from other PAH agents, (3) the maturity of the CTEPH treatment pathway, and (4) patent and line-extension dynamics.
What is Adempas (riociguat) approved to treat?
Key indications and label framing (region-specific in practice) include:
- PAH (WHO Group 1): Treatment to improve exercise capacity and delay clinical worsening in adults with idiopathic PAH (IPAH), heritable PAH (HPAH), or PAH associated with connective tissue disease (CTD-PAH), in WHO Functional Class (FC) II to III.
- CTEPH (WHO Group 4): Treatment of adults with persistent/recurrent CTEPH after surgical treatment, or inoperable CTEPH.
Source: U.S. prescribing information for Adempas. [1]
What does the clinical trials pipeline look like right now?
Are there active pivotal programs?
At the product level, recent public updates for riociguat have focused less on new core indication pivots and more on:
- optimized use within existing PAH and CTEPH populations,
- comparative or add-on strategies vs standard of care,
- outcomes in subgroups defined by disease severity, prior therapy, or treatment history.
However, as of the available public registry snapshot and product-level IP maturity, the most investable view is the absence of a clearly dominant, late-stage “new mechanism” repositioning program comparable to an additional registrational indication. That shifts risk-return toward market share defense and incremental labeling rather than a step-change expansion.
Where do registrational updates usually concentrate for Adempas?
Clinical development activity for riociguat is typically oriented around:
- PAH: refined role in combination therapy (e.g., sGC pathway continuity with background PAH therapies),
- CTEPH: expanding access or improving outcomes in surgical ineligible or persistent/recurrent patients,
- safety and efficacy in real-world-like subsets: dosing tolerance, hemodynamic endpoints, and functional class shifts.
Source: ClinicalTrials.gov search results and record-level activity for riociguat/Adempas. [2]
Note: This clinical trials “update” is limited to what is publicly visible at the registry and label level.
How is the Adempas market structured?
What patient segments drive demand?
Demand is anchored in two major disease pillars:
-
PAH (Group 1):
- chronic, high-acuity treatment population
- long duration therapy profile
- regimen complexity creates switching inertia
-
CTEPH (Group 4):
- persistent/recurrent after surgery and inoperable patients
- diagnosis pathway is narrower, but duration is long in the treated population
Because both settings require sustained medication, Adempas behaves like a chronic specialty product where the main commercial levers are:
- access and formulary coverage,
- competitive differentiation within PAH and CTEPH drug classes,
- adherence and dose management,
- clinician familiarity and guideline alignment.
Source: Adempas U.S. prescribing information and clinical endpoint basis. [1]
What are the competitive dynamics in PAH and CTEPH?
Where does Adempas compete most directly?
Within PAH, Adempas competes across the standard PAH mechanistic classes:
- endothelin receptor antagonists (ERAs),
- phosphodiesterase type 5 inhibitors (PDE5 inhibitors),
- prostacyclin pathway agents (including oral, inhaled, and injectable options),
- combination regimens where Adempas is part of the sGC axis.
Within CTEPH, the market is more constrained by the treatment pathway (surgery eligibility vs inoperable/persistent disease). In that segment, Adempas competes against other pharmacologic strategies and care pathways, with conversion dynamics tied to diagnostic identification and post-surgical outcomes.
Source: Label-based indication framing and PAH/CTEPH standard-of-care context. [1]
Is there evidence of a continuing demand base in mature markets?
What does label maturity imply commercially?
Adempas has been on the market long enough that most countries have:
- established payer policy frameworks,
- guideline-concordant prescribing patterns,
- stable clinical practice around risk stratification.
This maturity typically reduces peak-then-decline volatility seen in newer launches, but it does not eliminate revenue pressure from:
- competitor brand erosion (discounting, formulary changes),
- patient migration to alternatives with perceived tolerability advantages,
- tighter payer utilization management.
Source: U.S. label safety and dosing framework that supports ongoing use patterns. [1]
Adempas: 2024–2029 revenue projection framework
What projection assumptions drive the base case?
A business projection for Adempas is best modeled as a chronic specialty product with:
- low-to-mid single digit volume growth (diagnosis and treated pool expansion offset by mortality, switching, and access constraints),
- mid single digit net price erosion in competitive markets,
- mix shift based on PAH vs CTEPH access differences and regional formulary changes.
The framework below converts those drivers into a stylized global trajectory. It is designed for decision use (capacity planning, pipeline ROI thresholds, and competitive scenario weighting).
Base-case annual growth projection (stylized)
Because the request requires clinical trials update, market analysis, and projection but no region-specific revenue dataset was provided, the projection is expressed as an index (relative to 2024 revenue).
| Index model (2024 = 100) |
Year |
Revenue index |
YoY growth (model) |
| 2024 |
100 |
- |
| 2025 |
104 |
+4% |
| 2026 |
108 |
+4% |
| 2027 |
112 |
+4% |
| 2028 |
115 |
+3% |
| 2029 |
118 |
+3% |
Interpretation for business use
- Growth is sustained but gradually decelerates as price erosion and competitive switching offset pool expansion.
- The model is consistent with mature chronic specialty dynamics and limited indication expansion.
What are the key upside and downside risks to the projection?
Upside scenarios (revenue index can overshoot)
- faster-than-modeled conversion of eligible CTEPH patients into treated populations (especially post-surgical persistent/recurrent),
- improved payer access or broader guideline adoption in specific geographies,
- competitive tolerability advantages that translate into preference for sGC pathway therapy in combination regimens.
Downside scenarios (revenue index can undershoot)
- accelerated formulary tightening and increased prior authorization burden,
- stronger-than-modeled competitor penetration in PAH combination therapy,
- safety-related discontinuations or dosing constraints that reduce persistence.
Source anchors: label-based safety/dosing and chronic use profile. [1]
What should investors and R&D leaders track now?
Operational KPIs tied to market share defense
- patient persistence (dose adherence and discontinuation)
- payer coverage outcomes (step edits, prior authorization rates)
- subgroup prescribing shifts (PAH FC mix and CTEPH surgical history mix)
- dose optimization trends (titration success, adverse event-related interruption rates)
Clinical KPIs tied to incremental value
- hemodynamic endpoint durability (for PAH and CTEPH cohorts)
- time-to-clinical-worsening metrics in real-world-like settings
- subgroup safety signals (hypotension risk management, titration tolerability)
Source anchors: label safety and clinical endpoint framework. [1]
Key Takeaways
- Adempas (riociguat) is a mature chronic specialty therapy for PAH and CTEPH, with demand anchored in long-duration treatment and guideline-based use. [1]
- Publicly visible clinical activity is more focused on refinement within existing disease frameworks than on clearly new, registrational, step-change expansions. [2]
- A practical 2024–2029 projection for commercial planning is consistent with a gradual growth pattern under mature-market conditions: 2029 revenue index ~118 if 2024 is normalized to 100.
- The dominant business risks are payer access and price erosion versus pool conversion and persistence, with competitive PAH dynamics driving the shape of YoY changes.
FAQs
-
What is Adempas’ mechanism of action?
It is an oral soluble guanylate cyclase (sGC) stimulator used in PAH and CTEPH. [1]
-
Which two major patient populations drive Adempas demand?
Adults with PAH (WHO Group 1) and adults with persistent/recurrent or inoperable CTEPH (WHO Group 4). [1]
-
Are there clear late-stage registrational programs likely to expand indications soon?
Public registries and product maturity suggest incremental refinements rather than an obvious new registrational pivot at present. [2]
-
What market variable most directly affects Adempas revenues?
Payer coverage and net pricing, which influence access and persistence in a competitive PAH drug environment. [1]
-
What is the base-case projection for 2029 relative to 2024?
Using an index model where 2024 = 100, the base case reaches ~118 by 2029, reflecting continued but decelerating growth.
References
[1] U.S. Food and Drug Administration. (n.d.). Adempas (riociguat) prescribing information.
[2] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Riociguat (Adempas) trials.
